Click here to get full coverage on Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - simplywall.st

A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings  simplywall.st

A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - simplywall.st

Click here to get full coverage on Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily

Behavioral Patterns of AVBP and Institutional Flows  Stock Traders Daily

Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily

Click here to get full coverage on Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget

Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year?  Bitget

Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget

Click here to get full coverage on B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $37 - 富途牛牛

B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $37  富途牛牛

B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $37 - 富途牛牛

Click here to get full coverage on Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Notable Friday Option Activity: AVTR, GOOGL, AVBP - Nasdaq

Notable Friday Option Activity: AVTR, GOOGL, AVBP  Nasdaq

Notable Friday Option Activity: AVTR, GOOGL, AVBP - Nasdaq

Click here to get full coverage on AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates - Stock Titan

AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates  Stock Titan

AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 - MarketBeat

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00  MarketBeat

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00 - MarketBeat

Click here to get full coverage on ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha

ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy  Seeking Alpha

ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha

Click here to get full coverage on Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains - simplywall.st

Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains  simplywall.st

Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains - simplywall.st

Click here to get full coverage on Noteworthy Thursday Option Activity: GCT, AVBP, ENVX - Nasdaq

Noteworthy Thursday Option Activity: GCT, AVBP, ENVX  Nasdaq

Noteworthy Thursday Option Activity: GCT, AVBP, ENVX - Nasdaq

Click here to get full coverage on ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00 - MarketBeat

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00  MarketBeat

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00 - MarketBeat

Click here to get full coverage on (AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

(AVBP) Movement Within Algorithmic Entry Frameworks  Stock Traders Daily

(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Click here to get full coverage on ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)  Seeking Alpha

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha

Click here to get full coverage on ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP) - MarketBeat

ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP)  MarketBeat

ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP) - MarketBeat

Click here to get full coverage on ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts  MarketBeat

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation - simplywall.st

Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation  simplywall.st

Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation - simplywall.st

Click here to get full coverage on Notable Thursday Option Activity: AVBP, GRAL, APPN - Nasdaq

Notable Thursday Option Activity: AVBP, GRAL, APPN  Nasdaq

Notable Thursday Option Activity: AVBP, GRAL, APPN - Nasdaq

Click here to get full coverage on Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily

Trading Systems Reacting to (AVBP) Volatility  Stock Traders Daily

Trading Systems Reacting to (AVBP) Volatility - Stock Traders Daily

Click here to get full coverage on BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Australia

BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline  Investing.com Australia

BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Australia

Click here to get full coverage on ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo

ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib  MyChesCo

ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo

Click here to get full coverage on AVBP Stock Price, News & Analysis | Arrivent Biopharma - Stock Titan

AVBP Stock Price, News & Analysis | Arrivent Biopharma  Stock Titan

AVBP Stock Price, News & Analysis | Arrivent Biopharma - Stock Titan

Click here to get full coverage on ArriVent BioPharma expects to raise $75M from stock sale - The Business Journals

ArriVent BioPharma expects to raise $75M from stock sale  The Business Journals

ArriVent BioPharma expects to raise $75M from stock sale - The Business Journals

Click here to get full coverage on Growth Value: Can AVBP outperform in the next rally - Weekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn

Growth Value: Can AVBP outperform in the next rally - Weekly Risk Report & Smart Swing Trading Alerts  baoquankhu1.vn

Growth Value: Can AVBP outperform in the next rally - Weekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn

Click here to get full coverage on In DUSU polls, here’s how the fight between NSUI and AVBP has stacked up - The Indian Express

In DUSU polls, here’s how the fight between NSUI and AVBP has stacked up  The Indian Express

In DUSU polls, here’s how the fight between NSUI and AVBP has stacked up - The Indian Express

Click here to get full coverage on AVBP Stock Price and Chart — NASDAQ:AVBP - TradingView

AVBP Stock Price and Chart — NASDAQ:AVBP  TradingView

AVBP Stock Price and Chart — NASDAQ:AVBP - TradingView

Click here to get full coverage on ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha

ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP)  Seeking Alpha

ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha

Click here to get full coverage on AVBP IPO News - Cancer biotech ArriVent Biopharma files for a $100 million IPO - renaissancecapital.com

AVBP IPO News - Cancer biotech ArriVent Biopharma files for a $100 million IPO  renaissancecapital.com

AVBP IPO News - Cancer biotech ArriVent Biopharma files for a $100 million IPO - renaissancecapital.com

Click here to get full coverage on We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance

We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate  Yahoo Finance

We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance

Click here to get full coverage on AVBP IPO News - Cancer biotech ArriVent BioPharma sets terms for $150 million IPO - renaissancecapital.com

AVBP IPO News - Cancer biotech ArriVent BioPharma sets terms for $150 million IPO  renaissancecapital.com

AVBP IPO News - Cancer biotech ArriVent BioPharma sets terms for $150 million IPO - renaissancecapital.com

Click here to get full coverage on ArriVent BioPharma Reports First Quarter 2025 Financial Results - The Manila Times

ArriVent BioPharma Reports First Quarter 2025 Financial Results  The Manila Times

ArriVent BioPharma Reports First Quarter 2025 Financial Results - The Manila Times

Click here to get full coverage on ArriVent BioPharma (AVBP) Stock Price, News & Analysis - MarketBeat

ArriVent BioPharma (AVBP) Stock Price, News & Analysis  MarketBeat

ArriVent BioPharma (AVBP) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat

Discover the 3 Best-Performing Biotech IPO Stocks of 2024  MarketBeat

Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat

Click here to get full coverage on ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Manila Times

ArriVent BioPharma Reports Third Quarter 2024 Financial Results  The Manila Times

ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Manila Times

Click here to get full coverage on Telangana Schools Closed Today as AVBP Calls For State-wide Bandh, Here’s When Classes Will Resume - India.Com

Telangana Schools Closed Today as AVBP Calls For State-wide Bandh, Here’s When Classes Will Resume  India.Com

Telangana Schools Closed Today as AVBP Calls For State-wide Bandh, Here’s When Classes Will Resume - India.Com

Click here to get full coverage on NEET PG Aspirants Demand to Have Medical Entrance Twice a Year, AVBP Writes to Health Minister - News18

NEET PG Aspirants Demand to Have Medical Entrance Twice a Year, AVBP Writes to Health Minister  News18

NEET PG Aspirants Demand to Have Medical Entrance Twice a Year, AVBP Writes to Health Minister - News18

Click here to get full coverage on AVBP rally a let-down after hype - Telegraph India

AVBP rally a let-down after hype  Telegraph India

AVBP rally a let-down after hype - Telegraph India

Click here to get full coverage on A day after clash, AVBP demands suspension of station house officer of Sector 11 - The Indian Express

A day after clash, AVBP demands suspension of station house officer of Sector 11  The Indian Express

A day after clash, AVBP demands suspension of station house officer of Sector 11 - The Indian Express

Click here to get full coverage on Need to challenge AVBP’s impunity, says AISA’s DU head Kawalpreet Kaur | Latest News Delhi - Hindustan Times

Need to challenge AVBP’s impunity, says AISA’s DU head Kawalpreet Kaur | Latest News Delhi  Hindustan Times

AVBP

Price Chart

Key Statistics

Technicals

About AVBP

Latest News

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings - simplywall.st

Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily

Advanced Charts

Top Gainers

Top Losers